Loading
Adicet Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Apr 2026.
Adicet Bio, Inc.: what insiders have been doing
Adicet Bio, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Adicet Bio, Inc. logged 12 filings by 6 insiders.
Open-market activity splits into 3 purchases totalling €1.4M and 4 sales totalling €578k; 1 insider sit on the buying side and 1 insider on the selling side. Purchases outweigh sales by €781k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 1 major shareholder among the declarants. RA Capital Management, L.P. filed the largest purchase, €462k, on 13 April 2026.
The latest purchase dates back some time: it was published 188 days ago, on 13 April 2026. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 12 filings in twelve months, the company is quieter than the median of 19 filings across the 5,808 companies we follow on the same exchange. Our records for Adicet Bio, Inc. go back to 2021, with 8 purchases and 31 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -116.8 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
112
Thresholds
n/a
Buy Volume
€13M
8 ops. · all time
Sell Volume
€4M
31 ops. · all time
Who traded when
BuySaleOrbimed Advisors LLC1 buy4 sales
RA Capital Management, L.P.3 buys
Since the insiders bought
- +22.1%Entry US$7.00 · Close at T+90 US$8.55
- -67.4%Entry US$15.66 · Close 13 Oct 2026 US$5.11
- -30.5%Entry US$239.84 · Close at T+365 US$166.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Adicet Bio, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$33.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.00
Analyst consensus
6 analystsStrong buy
US$18.00Target US$33.17(+269%)US$90.00
Income statement
EBITDA-US$110.4M
Net income-US$116.8M0.0% margin
Valuation
PER (forward)-2.3x
P/Book0.8x
Beta1.59
Balance sheet & cash
Market capUS$84.3M
Total debtUS$14.7M
Free Cash Flow-US$97M
Debt / Equity11%
Profitability & ownership
ROE-78.1%
ROA-41.7%
% insiders1.1%
% institutions64.9%
Last declaration on 29 April 2026
Declarations112 total
250,000 sharesCommon StockSEC:0001231919-26-000425:0
74,577 shares@ US$7.0432.6% of flowCommon StockSEC:0001231919-26-000337:0
Canonical exit: 19 May 2026 (T+90)
74,268 shares@ US$7.2133.4% of flowCommon StockSEC:0001231919-26-000337:1
Canonical exit: 20 May 2026 (T+90)
74,751 shares@ US$7.2734.0% of flowCommon StockSEC:0001231919-26-000337:2
Canonical exit: 21 May 2026 (T+90)
29,319 shares@ US$6.531.9% of flowCommon StockSEC:0000947871-26-000421:0
2,400 shares@ US$6.380.1% of flowCommon StockSEC:0000947871-26-000421:1
32,523 shares@ US$6.292.0% of flowCommon StockSEC:0000947871-26-000421:2
40,416 shares@ US$6.522.6% of flowCommon StockSEC:0000947871-26-000421:3
535 shares@ US$8.440.7% of flowCommon StockSEC:0001193125-26-024755:0
546 shares@ US$8.443.0% of flowCommon StockSEC:0001193125-26-024746:0
1,755 shares@ US$8.440.4% of flowCommon StockSEC:0001193125-26-024749:0
535 shares@ US$8.441.5% of flowCommon StockSEC:0001193125-26-024753:0
1,500,000 shares@ US$1.0014.6% of flowCommon StockSEC:0000947871-25-000898:0
Canonical exit: 6 Jan 2026 (T+90)
5,900 shares0Common StockSEC:0000950170-25-086166:0
5,900 shares0Common StockSEC:0000950170-25-086163:0
5,900 shares0Common StockSEC:0000950170-25-086160:0
5,900 shares0Common StockSEC:0000950170-25-086157:0
5,900 shares0Common StockSEC:0000950170-25-086135:0
8,752 shares@ US$0.92185.9% of flowCommon StockSEC:0000950170-25-009827:0
28,101 shares@ US$0.92180.7% of flowCommon StockSEC:0000950170-25-009843:0
8,560 shares@ US$0.92183.0% of flowCommon StockSEC:0000950170-25-009839:0
6,270 shares@ US$0.92180.9% of flowCommon StockSEC:0000950170-25-009838:0
5,900 shares0Common StockSEC:0000950170-24-070575:0
5,900 shares0Common StockSEC:0000950170-24-070610:0
5,900 shares0Common StockSEC:0000950170-24-070577:0
25 of 112 declarations
About Adicet Bio, Inc.
Adicet Bio, Inc. (ticker: ACET) is a clinical-stage biotechnology company listed on the Nasdaq market in the United States (United States). For international equity investors, the name fits the profile of a high-risk, high-upside biopharma story built around an off-the-shelf allogeneic cell therapy platform based on gamma delta T cells. The company is focused on developing engineered T-cell therapies for autoimmune diseases and cancer, using CAR-enabled products designed to improve targeting, tissue homing and drug exposure. Its lead program is prula-cel (formerly ADI-001), a first-in-class allogeneic gamma delta T-cell therapy targeting CD20 and being advanced primarily in autoimmune indications such as lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), with additional expansion into other autoimmune settings. Adicet is also developing ADI-212, a next-generation gene-edited and armored candidate aimed at metastatic castration-resistant prostate cancer (mCRPC).
The company was founded in 2014 by Aya Jakobovits, with OrbiMed as an early backer, and its current public-company structure was shaped by the September 2020 merger with resTORbio. That transaction kept Adicet in the public markets while allowing it to sharpen its strategic focus on cell therapy. Today, Adicet operates with offices in Redwood City and Boston, and also maintains a presence in Shanghai. That footprint reflects a small but globally minded R&D organization rather than a commercial-stage footprint. The business remains clearly clinical and pre-commercial, so valuation is driven primarily by trial design, data quality, regulatory interactions and capital runway rather than near-term sales.
Read moreShow less
In competitive terms, Adicet occupies a niche but potentially differentiated segment of immunotherapy. Its gamma delta platform is designed to offer an allogeneic, scalable approach that may improve tolerability and make cell therapy more accessible across a broader set of diseases. That said, the company competes with much better capitalized biotech peers in autoimmune disease, hematology and solid tumors, making execution and data readouts essential. The key investment debate is whether its biology can translate into repeatable clinical signals strong enough to justify later-stage development and eventual partnering or commercialization.
Recent developments have been important. In early 2026, Adicet said enrollment in the Phase 1 autoimmune study of prula-cel had more than doubled to over 20 patients, and management guided to multiple clinical updates during 2026. The company also reported alignment with the FDA to enable outpatient dosing for certain LN and SLE patients, and it continued advancing ADI-212 toward a regulatory filing. Financially, Adicet raised capital in 2025, extending its cash runway into the second half of 2027, which is a meaningful consideration for investors assessing dilution risk and clinical optionality on Nasdaq.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
